Powering Pediatric Cures with Real-World Evidence

Powering Pediatric Cures with Real-World Evidence

HIMSS is committed to keeping your information safe. The information you provide will be used in accordance with our privacy policy.

Watch Now

First Name *

Last Name *

Email Address *

Company *

Job Title *

Job Role *

Work Phone *

Country *

City *

State *

Postal Code *

Industry *

Privacy

I am completing this form in connection with my: *

Business Interests

Personal interests

Yes, I'd like HIMSS to provide my contact information to Amazon Web Services (AWS) so AWS can share the latest AWS news and offers with me by email, post or telephone. You may unsubscribe from receiving news and offers from AWS at any time by following the instructions in the communications received. AWS handles your information as described in the AWS Privacy Notice.

In order to receive communications from HIMSS, please check this box.

Sponsored by:

Children diagnosed with diffuse midline glioma (DMG) or diffuse intrinsic pontine glioma (DIPG) generally have between nine and 11 months left to live. Join Mika Newton, CEO of xCures, and David Frigeri, managing director of healthcare data and analytics at

Slalom, as they discuss Slalom’s work with xCures. Part of that work involves building a healthcare AI and data technology platform on Amazon Web Services (AWS) to enable researchers to collect, organize and share clinical data that could help advance cures for these pediatric cancers.

Learn more about:

Slalom’s work on a website that gives DIPG/DMG patients’ parents information on clinical trials
Challenges involved in maintaining regulatory compliance for data used in clinical trials, as well as in drug and device submissions
How AI-driven tools like the xCures platform, built on Amazon Redshift and Amazon Bedrock, help provide researchers with clinical data more quickly

How healthcare data and AI are advancing pediatric cancer research